Research Triangle Park, North
Carolina
November 17, 2003
Paradigm Genetics,
Inc. (Nasdaq: PDGM), a biotechnology company, today
announced that it has signed a two-year extension of its
herbicide discovery collaboration with
Bayer CropScience,
which would take the partnership through September 2006. This
extension, the second since the initiation of this program, is
structured similarly to the base contract, to include research
funds and success fees for assay deliveries.
“We are very pleased that Bayer has elected to extend our
collaboration into 2006. This agreement underscores the vital
role we play in their herbicide discovery program and is a
strong validation of the sustained value of our research
capabilities,” said Heinrich Gugger, Ph.D., President and CEO
for Paradigm Genetics. “This extension will allow us to further
exploit for Bayer the large number of validated herbicide
targets discovered during this collaboration.”
"Our decision to extend this partnership with Paradigm Genetics
was based on the high level of success we have had to date with
this program,“ said Dr. Klaus Stenzel, Head of Global Target
Research of Bayer CropScience. “We’ve been impressed with the
quantity and quality of targets and assays Paradigm has
delivered. Together we are building a strong proprietary
position to secure the use of important genomic technologies in
herbicide research.”
Paradigm's herbicide partnership with Bayer began in October
1998 with the objective of discovering a portfolio of novel
herbicide products that will be developed and marketed by Bayer.
The term of the original agreement was three years with an
initial option to extend the relationship another two. The first
extension was signed in September 2001. To date, Paradigm has
analyzed thousands of plant genes, identified hundreds of novel
herbicide targets and delivered numerous assays for use in Bayer
CropScience's high throughput chemical screening facility.
Payments to Paradigm include committed research funds, fees for
assays delivered and milestone payments. The agreement includes
success fees and possible royalty payments to Paradigm for any
commercial herbicides that might emerge from the collaboration.
Paradigm is a biotechnology company driving R&D productivity
by focusing its integrated suite of technologies on the product
development cycle - from target discovery to the subsequent
enhancement of the safety and efficacy profiles of development
candidates in agriculture and human health. Paradigm chooses a
systems biology approach to understand gene function in the
context of biological pathways, and to develop assays and
biomarkers for molecular diagnostic solutions tailored to the
needs of our partners. Paradigm's proprietary Gene to Cell to
System™ approach has four major components: gene expression
profiling, biochemical profiling, phenotypic profiling and data
integration and coherence. |